Effects of 6-Month Sitagliptin Treatment on Glucose and Lipid Metabolism, Blood Pressure, Body Weight and Renal Function in Type 2 Diabetic Patients: A Chart-Based Analysis

BACKGROUND: Sitagliptin is one of the dipeptidyl peptidase-4 (DPP-4) inhibitors which prevent the inactivation of incretins, increasing the endogenous active incretin levels. Incretins stimulate insulin secretion from pancreatic β-cells and inhibit glucagon secretion from pancreatic α-cells, which i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanai, Hidekatsu, Adachi, Hiroki, Hamasaki, Hidetaka, Masui, Yoshinori, Yoshikawa, Reo, Moriyama, Sumie, Mishima, Shuichi, Sako, Akahito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409620/
https://www.ncbi.nlm.nih.gov/pubmed/22870172
http://dx.doi.org/10.4021/jocmr975w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409620/
https://www.ncbi.nlm.nih.gov/pubmed/22870172
http://dx.doi.org/10.4021/jocmr975w

Ejemplares similares